YSK Laboratories Private Limited

YSK Laboratories Private Limited (commonly branded as YSK Labs) is an Indian pharmaceutical manufacturing company based near Mumbai, Maharashtra. It describes itself as an R&D-driven company built on proprietary direct-compression technology, and it operates an integrated research and manufacturing facility that produces both Directly Compressible (DC) Granules and finished tablets under one roof. The company's business spans three areas. First, it supplies Directly Compressible (DC) Granules to formulators and finished-dosage-form (FDF) companies. DC Granules are described as a semi-formulated state of active pharmaceutical ingredients (APIs) that can be transformed into solid dosage forms in a single compression step, eliminating the need for granulation and drying. Second, YSK manufactures finished formulations — complete tablet and oral solid dosage products — both under its own branded generics and as a contract manufacturing partner for other pharmaceutical companies, with immediate-release (IR), sustained-release (SR), and extended-release (XR) capability. Third, it operates a nutraceutical division. According to its official website, YSK Labs' facility has an annual capacity of 400–500 metric tons of DC Granules and up to 500 million finished tablets per year. The company states that its products are manufactured in a WHO GMP and ISO 9001:2015 certified facility, and it emphasizes green and sustainable technology, an experienced scientific team, and proprietary in-house technology as the foundation of its offering. YSK positions itself across the pharmaceutical value chain: supplying formulators with DC Granules, manufacturing its own branded generics, and partnering with pharmaceutical companies as a contract manufacturer. Its stated benefits for formulators include a simplified manufacturing process, cost efficiency, faster time-to-market, enhanced product quality through consistent content uniformity and accurate dosing, and resource optimization. The company markets its SR/XR and IR products as distinguished by innovative manufacturing technologies, higher active ingredient content, and lower excipient loads. As a Private Limited company, YSK Laboratories is privately held. The available evidence does not disclose its founding year, founders, ownership structure, or executive leadership, and it does not indicate any stock exchange listing.

YSK Laboratories Private Limited is an Indian pharmaceutical company based near Mumbai, Maharashtra. Publicly available evidence about the company comes primarily from its own official website, which describes it as an R&D-driven pharmaceutical company dedicated to transforming pharmaceutical manufacturing through proprietary, in-house technology. According to the company, its origins lie in a breakthrough in Directly Compressible (DC) Granules. DC Granules are described as a semi-formulated state of active pharmaceutical ingredients (APIs) that eliminate the need for granulation and extensive processing, transforming into solid dosage forms (tablets) in a single compression step. From this starting point, YSK states that it grew into an integrated pharmaceutical company spanning three areas: DC Granules for formulators, finished-formulation tablet manufacturing under its own brands and for third-party partners, and a nutraceutical division. The company operates an integrated R&D and manufacturing facility near Mumbai that produces both DC Granules and finished tablets under one roof. It reports an annual capacity of 400–500 metric tons of DC Granules and up to 500 million finished tablets per year, and states that its products are manufactured in a WHO GMP and ISO 9001:2015 certified facility. YSK emphasizes green and sustainable technology, an experienced scientific team, and proprietary technology as the foundation of its operations. YSK positions itself across the pharmaceutical value chain: supplying formulators with DC Granules, manufacturing its own branded generics, and partnering with pharmaceutical companies as a contract manufacturer. It offers immediate-release (IR), sustained-release (SR), and extended-release (XR) capability, and markets its SR/XR and IR products as distinguished by innovative manufacturing technologies, higher active ingredient content, and lower excipient loads. The available evidence does not disclose the company's founding year, founders, ownership structure, or executive leadership. As a Private Limited company, YSK Laboratories is privately held, and there is no indication of a stock exchange listing.

An R&D-driven, integrated pharmaceutical manufacturer built on proprietary direct-compression technology, serving formulators, its own branded generics, and third-party contract manufacturing partners.

• Directly Compressible (DC) Granules

  Proprietary semi-formulated granules of APIs that transform into solid dosage forms in a single compression step, eliminating granulation and drying; custom-developed to specification.

• Finished formulation tablets (IR/SR/XR)

  Complete tablet and oral solid dosage manufacturing under YSK's own branded generics and as a contract manufacturing partner, with immediate-, sustained-, and extended-release capability.

• Nutraceuticals

  A nutraceutical range manufactured on the same R&D-driven, proprietary-technology foundation.

1. 1DC Granules & FDF Manufacturer India | Directly Compressible Granules | YSK Labsysklabs.com
2. 2About Us | Ysk Laboratories Pvtysklabs.com
3. 3Products | DC Granules, Finished Formulations & Nutraceuticals | YSK Labsysklabs.com
4. 4About YSK Labs | DC Granules & Finished Formulation Manufacturer Indiaysklabs.com
5. 5Wikidatawikidata.org